[Comment] Complexity of intermittent letrozole adjuvant therapy
To improve the outcomes of postmenopausal women with early-stage breast cancer is an important ongoing research goal. In The Lancet Oncology, Marco Colleoni and colleagues1 of the International Breast Cancer Study Group attempted to address this important research question in the Study Of Letrozole Extension (SOLE) trial in which they evaluate a novel approach to aromatase inhibitor administration —namely, extended intermittent use of adjuvant letrozole. At 5 years' follow-up, they report that disease-free survival did not differ significantly between women who received extended intermittent letrozole and those given continuous letrozole (hazard ratio 1·08, 95% CI 0·93–1·26; p=0·31).
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Rowan T Chlebowski, Kathy Pan Tags: Comment Source Type: research